Skip to main content
Clinical and Molecular Allergy : CMA logoLink to Clinical and Molecular Allergy : CMA
. 2021 Dec 20;19:27. doi: 10.1186/s12948-021-00166-5

Autism spectrum disorders and atopic dermatitis: a new perspective from country-based prevalence data

Alessandro Tonacci 1,, Giovanni Pioggia 2,#, Sebastiano Gangemi 3,#
PMCID: PMC8691085  PMID: 34930274

Abstract

Recently, a continuous growth for both neurodevelopmental and atopic diseases’ incidence was seen throughout the world. Notably, autism spectrum disorders (ASD) and atopic dermatitis (AD) attracted the attention of clinicians and scientists for their impact on the quality of life of patients, starting during childhood. Despite a number of hypotheses about common pathogenesis between the two disorders, uncertainty is still present, and data coming from various parts of the world are contradictory. Fortunately, works recently published have brought useful material for comparative analysis to the benefit of the scientific community, making large scale, country-based perspectives methodologically viable. In light of that, the present study took into account uniform data, available from country-based registries or related publications, dealing with the prevalence of the two conditions around the world, and tried to setup a simple correlation analysis between the two. According to such data, the growth of AD and ASD prevalence appear uncorrelated, leading to hypothesise that, if a common etiopathological pathway exists between the two conditions, they are likely to interact to each other due to a complex interplay of co-morbidities, genes and environmental players not enough explained by a simple correlation analysis. Such facts are worth investigation in future research.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12948-021-00166-5.

Keywords: Atopic dermatitis, Atopy, Autism spectrum disorders, Immune system, Neurodevelopmental disorders

Introduction

Atopic diseases are continuously growing in terms of worldwide prevalence even in infants and children, starting very early during infancy with atopic dermatitis (AD), followed by allergic rhinitis and asthma later in life [1], in the clinical pipeline known as the “atopic march” [2]. Their cause is not fully revealed, yet, but their increased global prevalence, particularly concerning AD, is not to be due to genetics alone, but can be attributable to an interplay with evolving environmental exposures, at least in predisposed individuals [3].

Notably, environmental agents, including pollutants and allergens, are associated with an increasing prevalence of the disease. Other environmental players, such as tobacco exposure, microbes, diet, nutrients, together with genetic variants, including filaggrin mutations, could lead to the deficiency of the skin barrier and the immune system, overall, paving the way for AD onset already early during life [4].

Quite surprisingly, atopic disorders [5], and in particular AD, were found to be somewhat associated with a number of psychiatric conditions, also starting during childhood [6, 7], among which autism spectrum disorders (ASD) are probably the best known and most prevalent worldwide.

Somewhat similarly to AD, also ASD pathogenesis is still unclear, but also in this case mounting evidence supports the hypothesis for a significant gene-environment interaction in its etiology [8].

A recent study on this topic attempted at making clarity based on population data from 5 countries (Denmark, Finland, Israel, Sweden and Western Australia). The authors found the heritability of ASD to be around 80%, with the variation in ASD occurrence mostly due to inherited genetic influences, and no evidence for related maternal effects [9]. Interestingly, the prevalence of AD in children living in Western countries is rising in a similar manner when compared to ASD, with hypothesised bidirectional association between them, suggesting a shared pathogenesis underlying the two, apparently far, conditions [1]. Several hypotheses were raised about a possible common pathway between the two disorders, including the dysregulation of common microRNAs, such as miR-146 and miR-155 [10], the co-existence of higher concentrations of pro-inflammatory cytokines in both atopic and neuropsychiatric disorders [11], or the action of overexpressed inflammatory mediators released during atopic responses that could have affected neural circuitry in genetically susceptible children [12].

More specifically, genetic variants in Stat6, pivotal element in the regulation of Th2 immune response, are known to be associated with atopy. But Stat6 is also found to be largely expressed in the central nervous system and to play a key role in the pathogenesis of some neuropsychiatric conditions, including ADHD, in turn largely co-morbid to ASD [6]. This, still indirect, possible association has further fostered the hypothesis for a somewhat connection between atopy and neuropsychiatric, or neurodevelopmental disorders.

Nevertheless, in this complex and quite puzzled framework, two of the largest population-based longitudinal studies published to date hypothesised a role for AD as an early precursor for ASD [13, 14]. According to the authors, toddlers affected from AD as young as 3 years old are at higher risk of developing ASD or ADHD later during childhood, especially in presence of other atopic comorbidities such as allergic rhinitis, allergic conjunctivitis, and asthma. Lee et al. [13] hypothesised a role for AD as a trigger for an immunological cascade comprising mast cells activation, in turn inducing the release of pro-inflammatory cytokines, mostly IL-6, whose levels were seen to be elevated in ASD patients and to modulate the autistic-like behaviour in animal models [15]. Such elevated cytokine levels found in ASD patients can bring to damage to the blood–brain barrier, in turn playing a key role in the etiopathogenesis of ASD and other neuropsychiatric conditions.

Both AD and ASD are actually under the magnifying glass of clinical research in the respective medical fields (allergology/immunology and pediatric neuropsychiatry, respectively) due to their increasing prevalence and to the attention of physicians and pharmaceutical industry. However, despite this fact, until a few years ago, the scientific literature experienced a lack of uniform correlation analyses between their respective prevalence in a significant number of nations from all over the world, except some isolated attempts to follow the prevalence trend of the two conditions longitudinally in a given country [1618]. This, apparently strange phenomenon, was possibly due to a lack of standardization in clinical criteria that might have prevented researchers from carrying out such analysis in a reliable fashion.

Fortunately, in more recent times, larger databases have been published, therefore allowing for more exhaustive comparisons between the data pertaining the two conditions. Indeed, a big amount of countries are now included within uniform data collection reported online (https://worldpopulationreview.com/country-rankings/autism-rates-by-country) or in scientific literature [19] for both conditions, making the analysis less complicated than before.

Materials and methods

In light of the still existing literature gap, and taking advantage of the novel, free data availability, we sought to correlate the information retrieved from [19] and https://worldpopulationreview.com/country-rankings/autism-rates-by-country between them, consisting of prevalence data from 186 countries dealing with AD and ASD prevalence worldwide. Statistical analysis was conducted using SPSS v.23 (IBM Corp., Armonk, NY, USA).

The distribution of the available data has driven us to adopt a non-parametric approach for correlations, using the two-tailed Spearman’s Test to verify the common trends for the two variables.

Results and discussion

As expected, possibly due to the hypothesised complexity in the interaction between those two conditions, statistical significance was not reached (r  = 0.061, p  = 0.412), but at the same time interesting observations can be derived. In fact, taking AD prevalence as the independent variable and, consequently, ASD prevalence as dependent, and attempting to fit the two variables compared to each other, the best fit occurred applying a cubic fit, with r2  = 0.049 and p  = 0.026. This leads to the hypothesis that a somewhat relationship between the two prevalence datasets could exist, even if its magnitude can be deemed as quite reduced. Figure 1 displays the resulting fit.

Fig. 1.

Fig. 1

Regression curve, with cubic fit, between AD and ASD prevalence in the 186 countries whose data are available (complete data available as Additional file 1)

As displayed, except for some outliers, the growth of ASD prevalence changes together with that of AD prevalence according to a cubic trend, possibly leading to consider the existence of a complex interplay between genes and environment in both AD and ASD, possibly suggesting a somewhat common etiopathological pathway between the two, disorders.

The main outliers are all represented by countries situated in the Middle East (Qatar, United Arab Emirates, Oman, Bahrain, Saudi Arabia), where ASD prevalence rates are surprisingly higher, without a similarity in any corresponding AD rise. This fact could be due to a number of external factors, possibly affecting the two conditions in a different manner. One of the possible, more reasonable explanations, is that Middle East countries have been experiencing a significant deficit in terms of serum Vitamin D levels, with several recommendations to undergo their supplementation already in women during pregnancy to prevent from bone diseases, immune malfunctioning and nervous system disturbances [20]. As such, hypovitaminosis D was associated with a higher risk of ASD pathogenesis [21], with convincing etiopathological explanations [22]. In addition, children with lower serum levels of Vitamin D appear to improve their clinical status after Vitamin D supplementation, with a significant reduction of psychiatric manifestations [23].

In addition, also AD severity was seen to be correlated with low levels of Vitamin D, and recent studies performed on infants confirmed this evidence [24, 25]. A possible role for Vitamin D in terms of symptoms improvements related to AD was suggested, with the optimal dosage of such compound seen to support a correct disease management and an improved clinical course [25, 26]. Such result is probably due to the fact that children with Vitamin D deficiency experience a weakness of the immune system, with lower levels of NKT lymphocytes and T-regulatory lymphocytes, and higher concentrations of interleukin-22, leading to the hypothesis for a proinflammatory alert state and for a significant weakness of the immune system in such individuals [25].

Conclusions

Under such premises, our study is intended to stimulate future studies on this topic. Such researches should require: (i) a correlation of wider amount of epidemiological data for AD and ASD, but also referring to other immune, as well as neurodevelopmental disorders, and to environmental data, as desirable and where possible; (ii) a deeper investigation about the etiopathological pathways linking the two conditions to explain possible overlapping and to hypothesise innovative treatments for both disorders.

Such future steps are mandatory to confirm the existence of a clear relationship between the etiopathology of AD and ASD and to tailor new investigations about such link in a more focused manner to address the gaps still existing in the scientific literature. Also, this would ultimately lead to a broader understanding of the overall framework involving atopy and neurodevelopmental disorders, their causality and, hopefully, innovative and reliable strategies for challenging such conditions already during toddlerhood and early childhood.

Supplementary Information

12948_2021_166_MOESM1_ESM.docx (18.6KB, docx)

Additional file 1: Table S1. Details about prevalence of ASD and AD in the retrieved countries.

Acknowledgements

Not applicable.

Authors’ contributions

AT: methodology, validation, formal analysis, investigation, data curation, writing—original draft, writing—review and editing; GP: conceptualization, methodology, validation, formal analysis, investigation, data curation, writing—original draft, writing—review and editing, supervision, project administration; SG: conceptualization, methodology, validation, formal analysis, investigation, data curation, writing—original draft, writing—review and editing, supervision, project administration. All authors read and approved the final manuscript.

Funding

None.

Availability of data and materials

The datasets generated and/or analysed during the current study are available in the repositories mentioned within the references [1, 35].

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Giovanni Pioggia and Sebastiano Gangemi contributed equally to this work

Contributor Information

Alessandro Tonacci, Email: atonacci@ifc.cnr.it.

Giovanni Pioggia, Email: giovanni.pioggia@irib.cnr.it.

Sebastiano Gangemi, Email: gangemis@unime.it.

References

  • 1.Dai YX, Tai YH, Chang YT, Chen TJ, Chen MH. Increased risk of atopic diseases in the siblings of patients with autism spectrum disorder: a nationwide population-based cohort study. J Autism Dev Disord. 2019;49(11):4626–4633. doi: 10.1007/s10803-019-04184-w. [DOI] [PubMed] [Google Scholar]
  • 2.Bantz SK, Zhu Z, Zheng T. The atopic march: progression from atopic dermatitis to allergic rhinitis and asthma. J Clin Cell Immunol. 2014;5(2):202. doi: 10.4172/2155-9899.1000202. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Kantor R, Silverberg JI. Environmental risk factors and their role in the management of atopic dermatitis. Exp Rev Clin Immunol. 2017;13(1):15–26. doi: 10.1080/1744666X.2016.1212660. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Mu Z, Zhang J. The role of genetics, the environment, and epigenetics in atopic dermatitis. Adv Exp Med Biol. 2020;1253:107–140. doi: 10.1007/978-981-15-3449-2_4. [DOI] [PubMed] [Google Scholar]
  • 5.Tonacci A, Billeci L, Ruta L, Tartarisco G, Pioggia G, Gangemi S. A systematic review of the association between allergic asthma and autism. Minerva Pediatr. 2017;69(6):538–550. doi: 10.23736/S0026-4946.16.04623-5. [DOI] [PubMed] [Google Scholar]
  • 6.Ahn HJ, Shin MK, Seo JK, Jeong SJ, Cho AR, Choi SH, Lew BL. Cross-sectional study of psychiatric comorbidities in patients with atopic dermatitis and nonatopic eczema, urticaria, and psoriasis. Neuropsychiatr Dis Treat. 2019;15:1469–1478. doi: 10.2147/NDT.S191509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Billeci L, Tonacci A, Tartarisco G, Ruta L, Pioggia G, Gangemi S. Association between atopic dermatitis and autism spectrum disorders: a systematic review. Am J Clin Dermatol. 2015;16(5):371–388. doi: 10.1007/s40257-015-0145-5. [DOI] [PubMed] [Google Scholar]
  • 8.Herbert MR. Contributions of the environment and environmentally vulnerable physiology to autism spectrum disorders. Curr Opin Neurol. 2010;23(2):103–110. doi: 10.1097/WCO.0b013e328336a01f. [DOI] [PubMed] [Google Scholar]
  • 9.Bai D, Yip BHK, Windham GC, Sourander A, Francis R, Yoffe R, Glasson E, Mahjani B, Suominen A, Leonard H, et al. Association of genetic and environmental factors with autism in a 5-country cohort. JAMA Psychiat. 2019;76(10):1035–1043. doi: 10.1001/jamapsychiatry.2019.1411. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Tonacci A, Bagnato G, Pandolfo G, Billeci L, Sansone F, Conte R, Gangemi S. MicroRNA cross-involvement in autism spectrum disorders and atopic dermatitis: a literature review. J Clin Med. 2019;8(1):88. doi: 10.3390/jcm8010088. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Zimmerman AW, Jyonouchi H, Comi AM, Connors SL, Milstien S, Varsou A, Heyes MP. Cerebrospinal fluid and serum markers of inflammation in autism. Pediatr Neurol. 2005;33(3):195–201. doi: 10.1016/j.pediatrneurol.2005.03.014. [DOI] [PubMed] [Google Scholar]
  • 12.Schmitt J, Buske-Kirschbaum A, Roessner V. Is atopic disease a risk factor for attention-deficit/hyperactivity disorder? A systematic review Allergy. 2010;65(12):1506–1524. doi: 10.1111/j.1398-9995.2010.02449.x. [DOI] [PubMed] [Google Scholar]
  • 13.Lee CY, Chen MH, Jeng MJ, Hsu JW, Tsai SJ, Bai YM, Hung GY, Yen HJ, Chen TJ, Su TP. Longitudinal association between early atopic dermatitis and subsequent attention-deficit or autistic disorder: a population-based case-control study. Medicine. 2016;95(39):e5005. doi: 10.1097/MD.0000000000005005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Liao TC, Lien YT, Wang S, Huang SL, Chen CY. Comorbidity of atopic disorders with autism spectrum disorder and attention deficit/hyperactivity disorder. J Pediatr. 2016;171:248–255. doi: 10.1016/j.jpeds.2015.12.063. [DOI] [PubMed] [Google Scholar]
  • 15.Wei H, Chadman KK, McCloskey DP, Sheikh AM, Malik M, Brown WT, Li X. Brain IL-6 elevation causes neuronal circuitry imbalances and mediates autism-like behaviors. Biochim Biophys Acta. 2012;1822(6):831–842. doi: 10.1016/j.bbadis.2012.01.011. [DOI] [PubMed] [Google Scholar]
  • 16.Asher MI, Montefort S, Björkstén B, Lai CK, Strachan DP, Weiland SK, Williams H, ISAAC Phase Three Study Group Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006;368(9537):733–743. doi: 10.1016/S0140-6736(06)69283-0. [DOI] [PubMed] [Google Scholar]
  • 17.Dai YX, Chen TJ, Chang YT. Ambulatory practice of dermatologists in Taiwan: a nationwide survey. J Chin Med Assoc. 2018;81(8):729–734. doi: 10.1016/j.jcma.2018.01.003. [DOI] [PubMed] [Google Scholar]
  • 18.Xu G, Strathearn L, Liu B, Bao W. Prevalence of autism spectrum disorder among US children and adolescents, 2014–2016. JAMA. 2018;319(1):81–82. doi: 10.1001/jama.2017.17812. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Laughter MR, Maymone MBC, Mashayekhi S, Arents BWM, Karimkhani C, Langan SM, Dellavalle RP, Flohr C. The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990–2017. Br J Dermatol. 2021;184(2):304–309. doi: 10.1111/bjd.19580. [DOI] [PubMed] [Google Scholar]
  • 20.Chakhtoura M, Rahme M, Chamoun N, El-Hajj FG. Vitamin D in the Middle East and North Africa. Bone Rep. 2018;8:135–146. doi: 10.1016/j.bonr.2018.03.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Pioggia G, Tonacci A, Tartarisco G, Billeci L, Muratori F, Ruta L, Gangemi S. Autism and lack of D3 vitamin: a systematic review. Res Autism Spectr Disord. 2014;8(12):1685–1698. doi: 10.1016/j.rasd.2014.09.003. [DOI] [Google Scholar]
  • 22.Principi N, Esposito S. Vitamin D deficiency during pregnancy and autism spectrum disorders development. Front Psychiatry. 2020;10:987. doi: 10.3389/fpsyt.2019.00987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Wang Z, Ding R, Wang J. The association between vitamin D status and autism spectrum disorder (ASD): a systematic review and meta-analysis. Nutrients. 2020;13(1):86. doi: 10.3390/nu13010086. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Esenboga S, Cetinkaya PG, Sahiner N, Birben E, Soyer O, Sekerel BE, Sahiner UM. Infantile atopic dermatitis: Serum vitamin D, zinc and TARC levels and their relationship with disease phenotype and severity. Allergol Immunopathol. 2021;49(3):162–168. doi: 10.15586/aei.v49i3.191. [DOI] [PubMed] [Google Scholar]
  • 25.Lipińska-Opałka A, Tomaszewska A, Kubiak JZ, Kalicki B. Vitamin D and immunological patterns of allergic diseases in children. Nutrients. 2021;13(1):177. doi: 10.3390/nu13010177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Imoto RR, Uber M, Abagge KT, Lima MN, Rosário NA, Carvalho VO. Vitamin D supplementation and severity of atopic dermatitis: pre-post assessment. Allergol Immunopathol. 2021;49(2):66–71. doi: 10.15586/aei.v49i2.67. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

12948_2021_166_MOESM1_ESM.docx (18.6KB, docx)

Additional file 1: Table S1. Details about prevalence of ASD and AD in the retrieved countries.

Data Availability Statement

The datasets generated and/or analysed during the current study are available in the repositories mentioned within the references [1, 35].


Articles from Clinical and Molecular Allergy : CMA are provided here courtesy of BMC

RESOURCES